logo
Share SHARE
FONT-SIZE Plus   Neg

Lilly : Late-stage Lung Cancer Trial Meets Primary Endpoint Of Overall Survival

Eli Lilly and Co. (LLY: Quote) announced Wednesday that the REVEL trial, a global Phase III study of ramucirumab in combination with chemotherapy in patients with second-line non-small cell lung cancer or NSCLC, showed a statistically significant improvement in the primary endpoint of overall survival in the ramucirumab-plus-docetaxel arm compared to the control arm of placebo plus docetaxel.

REVEL also showed a statistically significant improvement in progression-free survival in the ramucirumab arm compared to the control arm.

The global, randomized, double-blind REVEL trial compared ramucirumab and docetaxel to placebo and docetaxel in NSCLC patients whose disease has progressed after failure of prior platinum-based chemotherapy for locally advanced or metastatic disease. The study included nonsquamous and squamous NSCLC patients. The most common (>5% incidence) Grade >3 adverse events occurring at a higher rate on the ramucirumab-plus-docetaxel arm compared to the control arm were decreased white blood cell count (neutropenia/leukopenia), febrile neutropenia, fatigue/asthenia and hypertension.

Lilly said it plans to present data from the REVEL trial at an upcoming scientific meeting and intends to submit the first application of these data to regulatory authorities in 2014.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In a thumbs up for the Iceland bond market, investors strongly oversubscribed to a bench-marked bond offering by Arion Bank, as the Nordic island country warms up to possible easy access to international credit. Arion Bank issued bonds for 300 million euros and received bids of more than 675 million euros from about 100 investors. The bonds are 3-year instruments with a fixed 3.125 percent coupon. Pacific Investment Management Co. LLC, better known as PIMCO, said investors pulled $8.6 billion from its Total Return Fund in February, the lowest amount of monthly outflow since departure of bond guru Bill Gross last year. The outflows for the month of February from Pimco's flagship fund dropped... Sony said it plans to release its virtual-reality headset next year, giving gamers something more to cheer about when using their playstation 4 console.
comments powered by Disqus
Follow RTT